Country: Ирска
Језик: Енглески
Извор: HPRA (Health Products Regulatory Authority)
DANTRON POLOXALCOL
Mundipharma Pharmaceuticals Limited
500mg/37.5 Milligram
Capsules Hard
2011-05-20
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT CODALAX FORTE 500mg/37.5mg capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 500 mg Poloxamer 188 and 37.5 mg Dantron. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard (capsule) Opaque green/light brown, size 0, hard gelatin capsule marked ‘CXF’ and NAPP in white. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Use only in the treatment of analgesic induced constipation in the terminally ill patient. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Recommended dosage: Adults One or two capsules at bedtime. Children under 12 years Not recommended. Elderly As recommended by the physician. 4.3 CONTRAINDICATIONS 1. In common with other gastro-intestinal evacuants, CODALAX FORTE capsules should not be given when acute or painful conditions of the abdomen are present or when the cause of the constipation is thought to be intestinal obstruction. 2. Pregnancy and lactation. 3. Hypersensivity to any of the constituents of the product. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 23/05/2011_ _CRN 2099871_ _page number: 1_ 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE 1. Oral administration of dantron has been reported to cause liver or intestinal tumours in rats and mice. There is no sound evidence to conclude a no effect dose and therefore there may be a risk of such effects in humans. CODALAX FORTE use should therefore be restricted to the licensed indications. 2. In babies, children and patients wearing nappies there may be staining of the buttocks. This may lead to superficial sloughing of the skin. Therefore, CODALAX FORTE should not be given to infants in nappies and shou Прочитајте комплетан документ